Cargando…
Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells
BACKGROUND: Platinum plus paclitaxel is a first-line chemotherapy for ovarian cancer. Platinum resistance is a hot topic for many scholars, but drug resistance caused by paclitaxel is also a topic of concern. Currently, scholars believe that inhibition of MAPK signaling pathway may be an effective w...
Autores principales: | Fan, Li-li, Chen, Xi, Zhang, Xiao-yu, Li, Ze-min, Fan, Xue-mei, Shen, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466840/ https://www.ncbi.nlm.nih.gov/pubmed/32829374 http://dx.doi.org/10.12659/MSM.922612 |
Ejemplares similares
-
Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice
por: Chen, Xi, et al.
Publicado: (2016) -
Altered Mitochondrial Dynamics, Biogenesis, and Functions in the Paclitaxel-Resistant Lung Adenocarcinoma Cell Line A549/Taxol
por: Zhou, Xiang, et al.
Publicado: (2020) -
Pleuromutilin Inhibits Proliferation and Migration of A2780 and Caov-3 Ovarian Carcinoma Cells and Growth of Mouse A2780 Tumor Xenografts by Down-Regulation of pFAK2
por: Zhang, Bo, et al.
Publicado: (2020) -
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
por: Wu, Xiaoqiu, et al.
Publicado: (2020) -
LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1
por: Shi, Cong, et al.
Publicado: (2018)